Ultragenyx Pharmaceutical RARE EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's EPS (basic)?
- Ultragenyx Pharmaceutical (RARE) reported EPS (basic) of -$1.84 in Q1 2026.
- How has Ultragenyx Pharmaceutical's EPS (basic) changed year-over-year?
- Ultragenyx Pharmaceutical's EPS (basic) decreased by 17.2% year-over-year, from -$1.57 to -$1.84.
- What is the long-term trend for Ultragenyx Pharmaceutical's EPS (basic)?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's EPS (basic) has grown at a -3.4% compound annual growth rate (CAGR), from -$6.70 to -$5.83.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.